Skip to main content

. 1983 Jul;46(7):684–685. doi: 10.1136/jnnp.46.7.684

Novel drug of choice in Eaton-Lambert syndrome.

H Lundh, O Nilsson, I Rosén

PMCID: PMC1027495 PMID: 6310051

684

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

EATON L. M., LAMBERT E. H. Electromyography and electric stimulation of nerves in diseases of motor unit; observations on myasthenic syndrome associated with malignant tumors. J Am Med Assoc. 1957 Mar 30;163(13):1117–1124. doi: 10.1001/jama.1957.02970480021005. [DOI] [PubMed] [Google Scholar]
Elmqvist D., Lambert E. H. Detailed analysis of neuromuscular transmission in a patient with the myasthenic syndrome sometimes associated with bronchogenic carcinoma. Mayo Clin Proc. 1968 Oct;43(10):689–713. [PubMed] [Google Scholar]
Lechat P., Deysson G., Lemeignan M., Adolphe M. Toxicité aiguë comparée de quelques aminopyridines in vivo (souris) et in vitro (cultures cellulaires) Ann Pharm Fr. 1968 May;26(5):345–349. [PubMed] [Google Scholar]
Molgó J., Lundh H., Thesleff S. Potency of 3,4-diaminopyridine and 4-aminopyridine on mammalian neuromuscular transmission and the effect of pH changes. Eur J Pharmacol. 1980 Jan 11;61(1):25–34. doi: 10.1016/0014-2999(80)90378-7. [DOI] [PubMed] [Google Scholar]

ACTIONS

RESOURCES